Evommune reprices director Arthur S. Kirsch’s options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. (EVMN) director Arthur S. Kirsch’s outstanding options were amended on November 13, 2026, with each old option deemed canceled and a replacement option granted. The options covered 37,960 shares at an original $16.00 exercise price and 15,673 shares at an original $19.82 exercise price; both replacement options have a $7.63 exercise price per share.
For exercises before the earlier of November 13, 2027 and a Change in Control during his Continuous Service, the terms require a premium exercise price equal to the original per-share price. One-third of the shares under the 37,960-share award vested on November 5, 2026, with the remaining shares vesting in 24 equal monthly installments subject to continued service. The 15,673-share award vests at the earlier of June 2, 2027 and Evommune’s next annual meeting, also subject to continued service. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to buy) F1, F2, F3 | 37,960 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F1, F2, F3 | 37,960 | -- | -- |
| Disposition | Stock Option (Right to buy) F4, F2, F5 | 15,673 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F4, F2, F5 | 15,673 | -- | -- |
Footnotes (5)
- F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
- F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
- F3. One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026.
- F5. The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Key Terms
Option Repricing technical
Change in Control technical
Continuous Service technical
2025 Equity Incentive Plan technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did EVMN director Arthur S. Kirsch have repriced?
AI-generated analysis. How Rhea-AI works. Not financial advice.